297 related articles for article (PubMed ID: 15365066)
1. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
3. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
[TBL] [Abstract][Full Text] [Related]
4. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
5. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Dang C; Fornier M; Sugarman S; Troso-Sandoval T; Lake D; D'Andrea G; Seidman A; Sklarin N; Dickler M; Currie V; Gilewski T; Moynahan ME; Drullinsky P; Robson M; Wasserheit-Leiblich C; Mills N; Steingart R; Panageas K; Norton L; Hudis C
J Clin Oncol; 2008 Mar; 26(8):1216-22. PubMed ID: 18323546
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
7. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Perez EA; Suman VJ; Davidson NE; Sledge GW; Kaufman PA; Hudis CA; Martino S; Gralow JR; Dakhil SR; Ingle JN; Winer EP; Gelmon KA; Gersh BJ; Jaffe AS; Rodeheffer RJ
J Clin Oncol; 2008 Mar; 26(8):1231-8. PubMed ID: 18250349
[TBL] [Abstract][Full Text] [Related]
8. HER2 and response to paclitaxel in node-positive breast cancer.
Hayes DF; Thor AD; Dressler LG; Weaver D; Edgerton S; Cowan D; Broadwater G; Goldstein LJ; Martino S; Ingle JN; Henderson IC; Norton L; Winer EP; Hudis CA; Ellis MJ; Berry DA;
N Engl J Med; 2007 Oct; 357(15):1496-506. PubMed ID: 17928597
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
10. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
Bianchi G; Albanell J; Eiermann W; Vitali G; Borquez D; Viganò L; Molina R; Raab G; Locatelli A; Vanhauwere B; Gianni L; Baselga J
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5944-51. PubMed ID: 14676119
[TBL] [Abstract][Full Text] [Related]
11. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
[TBL] [Abstract][Full Text] [Related]
12. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
13. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Morris PG; Dickler M; McArthur HL; Traina T; Sugarman S; Lin N; Moy B; Come S; Godfrey L; Nulsen B; Chen C; Steingart R; Rugo H; Norton L; Winer E; Hudis CA; Dang CT
J Clin Oncol; 2009 Dec; 27(36):6117-23. PubMed ID: 19901120
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
17. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
Loesch D; Greco FA; Senzer NN; Burris HA; Hainsworth JD; Jones S; Vukelja SJ; Sandbach J; Holmes F; Sedlacek S; Pippen J; Lindquist D; McIntyre K; Blum JL; Modiano MR; Boehm KA; Zhan F; Asmar L; Robert N
J Clin Oncol; 2010 Jun; 28(18):2958-65. PubMed ID: 20479419
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
19. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
